당뇨병성 신경장애 시장 규모, 점유율, 성장 분석 : 질환 유형별, 약제 클래스별, 유통 채널별, 지역별 - 산업별 예측(2024-2031년)
Diabetic Neuropathy Market Size, Share, Growth Analysis, By Disorder Type (Peripheral Neuropathy, Autonomic Neuropathy), By Drug Class (Capsaicin, Opioid), By Distribution Channel, By Region - Industry Forecast 2024-2031
상품코드:1619179
리서치사:SkyQuest
발행일:2024년 12월
페이지 정보:영문 165 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 당뇨병성 신경장애 시장 규모는 2022년에 36억 달러로 평가되며, 2023년 38억 5,000만 달러에서 2031년에는 65억 6,000만 달러로 성장하며, 예측 기간(2024-2031년)의 CAGR은 6.9%로 성장할 전망입니다.
당뇨병성 신경장애는 고혈당으로 인해 신경이 손상되는 질환으로 장기적인 당뇨병 환자들에게 큰 문제가 되고 있습니다. 현재 치료법이 없기 때문에 효과적인 관리와 예방 전략이 매우 중요합니다. 이러한 복잡성은 규제 당국이 새로운 치료제와 치료 접근법을 승인할 필요성을 강조하고 있습니다. 당뇨병 환자의 당뇨병성 신경병증 유병률이 높기 때문에 이 분야에서 사업을 도입하는 기업에게는 큰 시장 기회가 존재합니다. 인식과 진단이 향상됨에 따라 당뇨병 환자의 요구를 충족시키는 혁신적인 솔루션에 대한 수요가 급증할 것으로 예상되며, 이는 헬스케어 시장 성장과 개척에 유리한 전망을 제시할 것입니다.
목차
서론
조사의 목적
조사 범위
정의
조사 방법
정보 조달
2차 데이터와 1차 데이터 방법
시장 규모 예측
시장의 전제조건과 제한
개요
세계 시장 전망
공급과 수요의 동향 분석
부문별 기회 분석
시장 역학과 전망
시장 개요
시장 규모
시장 역학
촉진요인과 기회
억제요인과 과제
Porter의 산업 분석
주요 시장 인사이트
주요 성공 요인
경쟁의 정도
주요 투자 기회
시장 에코시스템
시장의 매력 지수(2023년)
PESTEL 분석
거시경제 지표
밸류체인 분석
가격 분석
기술의 진보
규제 상황
사례 연구
당뇨병성 신경장애 시장 규모 : 질환 유형별
시장 개요
말초신경병증
자율 신경 장애
근위신경장애
국소 신경장애
당뇨병성 신경장애 시장 규모 : 약제 클래스별
시장 개요
캅사이신
오피오이드
모르핀
기타
비스테로이드성 항염증약(NSAID)
이부프로펜
나프록센
항우울제
삼환계 항우울제(Tcas)
Amitriptyline
Imipramine
Serotonin and Norepinephrine Reuptake Inhibitors (Snris)
Duloxetine
Selective Serotonin Reuptake Inhibitors (Ssris)
Citalopram
Paroxetine
항경련약
Gabapentin
Pregabalin
Topiramate
기타
당뇨병성 신경장애 시장 규모 : 유통 채널별
시장 개요
병원 약국
소매 약국
당뇨병성 신경장애 시장 규모
북미
미국
캐나다
유럽
독일
스페인
프랑스
영국
이탈리아
기타 유럽 지역
아시아태평양
중국
인도
일본
한국
기타 아시아태평양
라틴아메리카
브라질
기타 라틴아메리카 지역
중동 및 아프리카
GCC 국가
남아프리카공화국
기타 중동 및 아프리카
경쟁 정보
상위 5사의 비교
주요 기업의 시장 포지셔닝(2023년)
주요 시장 기업이 채택한 전략
시장의 최근 동향
기업의 시장 점유율 분석(2023년)
주요 기업의 기업 개요
회사 개요
제품 포트폴리오 분석
부문별 점유율 분석
매출의 전년대비 비교(2021-2023)
주요 기업 개요
Abbott Laboratories
Eli Lilly and Company
Pfizer Inc.
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline plc
Lupin Pharmaceuticals, Inc.
Astellas Pharma US, Inc.
Bayer AG
Teva Pharmaceutical Industries Ltd.
NeuroMetrix Inc.
Helixmith Co., Ltd.
Johnson & Johnson Services, Inc.
Daiichi Sankyo Company, Limited
Ionis Pharmaceuticals, Inc.
Akcea Therapeutics, Inc.
Alfasigma USA, Inc.
ExeGi Pharma LLC
결론과 권장사항
KSA
영문 목차
영문목차
Global Diabetic Neuropathy Market size was valued at USD 3.6 billion in 2022 and is poised to grow from USD 3.85 billion in 2023 to USD 6.56 billion by 2031, growing at a CAGR of 6.9% during the forecast period (2024-2031).
Diabetic neuropathy, a nerve-damaging condition linked to hyperglycemia, poses significant challenges for long-term diabetes sufferers, where symptoms often go unnoticed until considerable nerve damage occurs. As there is currently no cure, effective management and preventive strategies are crucial. This complexity emphasizes the need for regulatory agencies to approve new treatment products and therapeutic approaches. With the high prevalence of diabetic neuropathy among individuals with diabetes, there exists a substantial market opportunity for companies operating in this sector. As awareness and diagnosis improve, businesses can expect a surge in demand for innovative solutions tailored to address the needs of those affected by this condition, presenting lucrative prospects for growth and development in the healthcare market.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Diabetic Neuropathy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Diabetic Neuropathy Market Segmental Analysis
Global Diabetic Neuropathy Market is segmented by disorder type, drug class, distribution channel and region. Based on disorder type, the market is segmented into peripheral neuropathy, autonomic neuropathy, proximal neuropathy and focal neuropathy. Based on drug class, the market is segmented into capsaicin, opioid, non-steroidal anti-inflammatory drugs (NSAIDS), antidepressants and other. Based on distribution channel, the market is segmented into hospitals pharmacies and retail pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Diabetic Neuropathy Market
The Global Diabetic Neuropathy market is primarily driven by the increasing prevalence of diabetes worldwide, leading to a higher demand for diabetic neuropathy treatment. As diabetes rates continue to rise, the market is expected to experience steady growth throughout the forecast period. Contributing factors include the rise in obesity, coronary heart disease, and various complications associated with diabetes, such as neuropathy. Additionally, urbanization plays a significant role in this trend, fostering sedentary lifestyles characterized by increased carbohydrate intake and reduced physical activity, which further exacerbates the incidence of diabetes and, consequently, the need for effective management of diabetic neuropathy.
Restraints in the Global Diabetic Neuropathy Market
The Global Diabetic Neuropathy market faces several restraints that impede its growth potential. One significant challenge is the high cost of medications specifically designed for treating this condition, which may deter patients from pursuing pharmaceutical options. Additionally, the increasing popularity of alternative treatments, such as radiotherapy and physiotherapy, presents competition as these methods are often perceived as more comfortable and capable of delivering satisfactory results. Furthermore, stringent regulations, instances of product recalls, and delays in obtaining clearances from regulatory bodies like the Food and Drug Administration also contribute to the difficulties faced by the market in expanding its reach and efficacy.
Market Trends of the Global Diabetic Neuropathy Market
The Global Diabetic Neuropathy market is witnessing a dynamic trend characterized by innovations in high-tech therapeutic solutions aimed at enhancing treatment efficacy. During the forecast period, companies are focusing on developing advanced products, including transdermal patches, mouthwashes, and powders, to address the complexities of diabetic neuropathy. The introduction of sophisticated medication delivery systems, such as needle-free injection devices, is emerging as a key strategy to mitigate challenges associated with traditional pharmaceutical methods. This surge in demand for novel drug delivery forms-spanning oral, transdermal, parenteral, and inhalation routes-is propelling market growth, reflecting an increasing consumer and healthcare provider interest in effective management of the condition.
Table of Contents
Introduction
Objectives of the Study
Scope of the Report
Definitions
Research Methodology
Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations
Executive Summary
Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis
Market Dynamics & Outlook
Market Overview
Market Size
Market Dynamics
Drivers & Opportunities
Restraints & Challenges
Porters Analysis
Competitive rivalry
Threat of substitute
Bargaining power of buyers
Threat of new entrants
Bargaining power of suppliers
Key Market Insights
Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2023
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Technological Advancement
Regulatory Landscape
Case Studies
Global Diabetic Neuropathy Market Size by Disorder Type & CAGR (2024-2031)
Market Overview
Peripheral Neuropathy
Autonomic Neuropathy
Proximal Neuropathy
Focal Neuropathy
Global Diabetic Neuropathy Market Size by Drug Class & CAGR (2024-2031)
Market Overview
Capsaicin
Opioid
Morphine
Others
Non-Steroidal Anti-Inflammatory Drugs (Nsaids)
Ibuprofen
Naproxen
Antidepressants
Tricyclic Antidepressants (Tcas)
Amitriptyline
Imipramine
Serotonin and Norepinephrine Reuptake Inhibitors (Snris)
Duloxetine
Selective Serotonin Reuptake Inhibitors (Ssris)
Citalopram
Paroxetine
Anticonvulsant Drugs
Gabapentin
Pregabalin
Topiramate
Other
Global Diabetic Neuropathy Market Size by Distribution Channel & CAGR (2024-2031)
Market Overview
Hospitals Pharmacies
Retail Pharmacies
Global Diabetic Neuropathy Market Size & CAGR (2024-2031)
North America (Disorder Type, Drug Class, Distribution Channel)
USA
Canada
Europe (Disorder Type, Drug Class, Distribution Channel)
Germany
Spain
France
UK
Italy
Rest of Europe
Asia Pacific (Disorder Type, Drug Class, Distribution Channel)
China
India
Japan
South Korea
Rest of Asia-Pacific
Latin America (Disorder Type, Drug Class, Distribution Channel)
Brazil
Rest of Latin America
Middle East & Africa (Disorder Type, Drug Class, Distribution Channel)